ACT Brief: SCOPE Highlights Operational Discipline, AI Adoption Accelerates Execution, and FDA Rethinks Evidence Standards

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• From our SCOPE Summit wrap up feature article, leaders emphasized that accelerating clinical trials depends on aligning data discipline with early operational planning and sustained patient engagement. Speakers reinforced that decisions made before the first patient is enrolled continue to shape timelines, while also stressing that reducing unnecessary data collection and rebuilding community trust remain essential to improving both efficiency and participation.
• In the fourth and final part of her video interview with ACT, Angela Zubel of Debiopharm said sponsors that move early on AI adoption and standardized data infrastructure are already seeing measurable efficiency gains. She pointed to real-time data access and automation across documentation workflows as areas delivering immediate operational impact, adding that organizations willing to experiment responsibly are gaining an edge in both speed and cost control.
• The FDA is expected to shift toward allowing a single adequate and well-controlled trial, supported by confirmatory evidence, as the default standard for new drug approvals. The change reflects advances in biomarker science and trial design, with regulators placing greater emphasis on study quality over quantity as they look to accelerate development without lowering evidentiary standards.

That’s all for today’s ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.